2Tefferi A,Thiele J,Orai A,et al. Proposals and rational for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendation from an ad hoe international expert panel[ J]. Blood, 2007,110(4) :1092 - 1097.
3Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms:The 2008 World Health Organization criteria and point - of - care diagnostic algorithms [ J ]. Leukmia, 2008,22 (1) :14 -22.
4Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet,2005,365 (9464) :1054 - 1061.
5Kralocics R, Passamonti F, Buser AS, et al. A gain - of -function mutation of JAK2 in myeloproliferative disorders [ J ]. N Engl J Med ,2005,352 ( 17 ) : 1779 - 1790.
6James C, Ugo V, Le Couedic JP, et al. A unique elonal JAK2 mutation leading to constitutive signalling causes polycythaemia veto [ J ]. Nature ,2005,434 (7037) : 1144 - 1148.
7Steensma DP,Dewald GW,Lasho TL,et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both " atypical" myeloproliferative disorders and myelodysplastic syndromes [ J ]. Blood,2005,106 (4) : 1207 - 1209.
8Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[ J]. N Engl J Med, 2007,356 (5) :459 - 468.
9Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders [ J ]. Leuk Lymphoma ,2006,47 (3) : 381 - 396.
10Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders:status report and immediate implications for disease classification and diagnosis [ J ]. Mayo Clin Proc, 2005,80(7) :947 -958.
